Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P58872
UPID:
RHBL3_HUMAN
Alternative names:
Ventrhoid transmembrane protein
Alternative UPACC:
P58872; A6NMH1; Q495Y4; Q495Y5; Q495Y6
Background:
Rhomboid-related protein 3, also known as Ventrhoid transmembrane protein, plays a crucial role in regulated intramembrane proteolysis, facilitating the release of functional polypeptides from their membrane anchors. This process is vital for cellular communication and signaling.
Therapeutic significance:
Understanding the role of Rhomboid-related protein 3 could open doors to potential therapeutic strategies. Its involvement in key cellular processes highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.